Atypical Clinical Course of Griscelli Syndrome Type 2 With Primarily Neurologic Presentation and Adult‐Onset in a 46‐Year‐Old Male
American Journal of Medical Genetics Part A · 2026-08 · 200 (8) · 1850-1855
DOI: 10.1002/ajmg.a.70140 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 18.03.2026. Verfasst von Dzhoy Papingi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: rab27 GTP-Binding Proteins, Piebaldism, Lymphohistiocytosis, Hemophagocytic, Primary Immunodeficiency Diseases. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Griscelli Syndrome Type 2 (GS2) is a rare autosomal recessive disorder caused by pathogenic mutations in the RAB27A gene. Typically, it is characterized by cutaneous hypopigmentation, immunodeficiency, with or without neurological abnormalities secondary to hemophagocytic lymphohistiocytosis (HLH). Without treatment, GS2 often results in fatal outcomes within the first decade of life. Adult‐onset GS2 is extremely rare, with few documented cases. We describe a 48‐year‐old patient with a neurological presentation: cerebellar dysarthria, ataxia, nystagmus, and muscle hypotonia in the lower limbs. Diagnostic workup included next‐generation sequencing (NGS panel), clinical investigations, and segregation analysis in the family to confirm the diagnosis of GS2. Genetic testing revealed two variants in RAB27A : The likely pathogenic c.550C>T [p.(Arg184*)] and c.213G>T [p.(Gln71His)], a variant of uncertain significance. Clinical evaluation confirmed irregular hair pigmentation due to melanosome transport defect, low natural killer cell activity, cytopenia, hypertriglyceridemia, elevated serum ferritin, and brain tissue biopsy compatible with hemophagocytosis, thus cementing the clinical diagnosis of GS2. Segregation analysis confirmed the trans configuration of the variants. Based on the clinical and genetic evidence, the p.Gln71His variant was reclassified as likely pathogenic per ACMG criteria. This rare late‐onset GS2 case highlights the need to consider GS2 in adult patients with atypical presentations. Early diagnosis is vital for effective intervention. Greater clinical awareness and research are needed to understand its phenotypic spectrum in adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Clinic for Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- MGZ-Medizinisch Genetisches Zentrum, Munich, Germany.
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Zitieren
APA
Papingi, D., Kutsche, M., Lichtenfeld, H., Kortüm, F., Abicht, A., Herrmann, L., & Herget, T. (2026). Atypical Clinical Course of Griscelli Syndrome Type 2 With Primarily Neurologic Presentation and Adult‐Onset in a 46‐Year‐Old Male. American Journal of Medical Genetics Part A, 200(8), 1850-1855. https://doi.org/10.1002/ajmg.a.70140
Vancouver
Papingi D, Kutsche M, Lichtenfeld H, Kortüm F, Abicht A, Herrmann L, et al. Atypical Clinical Course of Griscelli Syndrome Type 2 With Primarily Neurologic Presentation and Adult‐Onset in a 46‐Year‐Old Male. American Journal of Medical Genetics Part A. 2026;200(8):1850-1855. doi:10.1002/ajmg.a.70140
BibTeX
@article{Papingi2026,
author = {Papingi, Dzhoy and Kutsche, Michael and Lichtenfeld, Helena and Kortüm, Fanny and Abicht, Angela and Herrmann, Laura and Herget, Theresia},
title = {Atypical Clinical Course of Griscelli Syndrome Type 2 With Primarily Neurologic Presentation and Adult‐Onset in a 46‐Year‐Old Male},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
volume = {200},
number = {8},
pages = {1850--1855},
doi = {10.1002/ajmg.a.70140}
}
EUVIMED